The latest news about RNA-seq, gene expression profiling, and transcriptome sequencing.
The study found immunomodulatory and angiogenesis gene expression signatures, mutational profiles, and HLA types could help predict how patients respond to therapy.
A new study found that FOXA1 missense mutations were enriched in metastatic breast tumors and were associated with lower response to aromatase inhibitors.
GeneCentric's RNA-based molecular profiling platform will identify relevant non-muscle invasive bladder cancer subtypes and markers for potential therapeutic options.
Comprehensive analysis by a team led by Elaine Mardis has given 93 percent of around 150 pediatric cancer patients at least one medically actionable finding.
The platform was used to subtype patients in a Phase II trial and found that patients in the claudin-low subgroup had the best two-year progression-free survival on pembrolizumab.
